Clearside Biomedical (NASDAQ:CLSD) reported quarterly losses of $(0.10) per share which met the analyst consensus estimate. This is a 25 percent decrease over losses of $(0.08) per share from the same period last year. The company reported quarterly sales of $306.00 thousand which beat the analyst consensus estimate of $176.67 thousand by 73.21 percent. This is a 95.18 percent decrease over sales of $6.34 million the same period last year.